| Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. | |
| | |
MedLine Citation:
|
PMID: 21392603 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Kawasaki disease (KD) is a multisystem vasculitis affecting coronary arteries in children. Patients, refractory to standard treatment with intravenous immunoglobulin and aspirin, show higher rates of coronary artery dilation. Early tumor necrosis factor α receptor antagonism in KD may provide effective adjunctive therapy. STUDY DESIGN: The EATAK trial is a multicenter, double-blind, randomized, and placebo-controlled trial intended to assess the efficacy of etanercept in reducing the intravenous immunoglobulin refractory rate during treatment of acute KD. Each arm will enroll 110 patients who will receive 3 doses of study drug over 2 weeks in conjunction with standard therapy. Coronary artery dilation parameters will serve as secondary end points. DISCUSSION: The EATAK trial will test a new paradigm for treatment of acute KD involving tumor necrosis factor α antagonism by etanercept. |
| | |
Authors:
|
Michael A Portman; Aaron Olson; Brian Soriano; Nagib Dahdah; Richard Williams; Edward Kirkpatrick |
Related Documents
:
|
9033463 - Familial intracranial aneurysms. 355913 - The treatment of intracranial aneurysms by injection with a tissue adhesive. 6854373 - Detachable calibrated-leak balloon for superselective angiography and embolization of d... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: American heart journal Volume: 161 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-03-11 Completed Date: 2011-05-26 Revised Date: 2011-06-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 494-9 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2011 Mosby, Inc. All rights reserved. |
Affiliation:
|
Seattle Children's Hospital, WA 98101, USA. michael.portman@seattlechildrens.org |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00841789 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Coronary Vessels
/
pathology Dilatation, Pathologic Endpoint Determination Humans Immunoglobulin G / administration & dosage, therapeutic use* Immunoglobulins, Intravenous / therapeutic use Immunologic Factors / therapeutic use Receptors, Tumor Necrosis Factor / administration & dosage, antagonists & inhibitors*, therapeutic use Research Design |
| Grant Support | |
ID/Acronym/Agency:
|
R01-FD-003526/FD/FDA HHS |
| Chemical | |
Reg. No./Substance:
|
0/Immunoglobulin G; 0/Immunoglobulins, Intravenous; 0/Immunologic Factors; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mes...
Next Document: High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from pri...